University Hospital of Leceister NHS TRUST
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
walter, Harriet
NCT03568656 / 2018-000285-10: Study to Evaluate CCS1477 in Advanced Tumours

Recruiting
1/2
350
Europe, US
CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
CellCentric Ltd.
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
12/24
12/24
Keynote-D20, NCT04752826 / 2020-002090-10: BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies

Recruiting
1/2
176
Europe, US, RoW
BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
BioInvent International AB, Merck Sharp & Dohme LLC
Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
12/26
01/28
CCS1477-02, NCT04068597 / 2019-000104-15: Study to Evaluate CCS1477 in Haematological Malignancies

Recruiting
1/2
250
Europe, US
CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax
CellCentric Ltd.
Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
06/25
06/25
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26

Download Options